Results 11 to 20 of about 17,630,315 (317)

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion [PDF]

Nature, 2013
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers[superscript 1, 2, 3, 4, 5 ...
Anderson, Ana C., Beauchemin, Nicole, Blumberg, Richard S., Chen, Qiang, Clayton, Kiera L., Dougan, Stephanie K., Franke, Andre, Gandhi, Amit, Glickman, Jonathan N., Huang, Yu-Hwa, Kondo, Yasuyuki, Kuchroo, Vijay K., Melum, Espen, Ostrowski, Mario A., Pertel, Thomas, Petersen, Britt-Sabina, Petsko, Gregory A., Ploegh, Hidde, Pyzik, Michal, Raab, Monika, Rudd, Christopher E., Russell, Andrew, Yazaki, Paul J., Zhu, Chen   +23 more
core   +5 more sources

TIM-3 in Leukemia; Immune Response and Beyond [PDF]

Frontiers in Oncology, 2021
T cell immunoglobulin and mucin domain 3 (TIM-3) expression on malignant cells has been reported in some leukemias. In myelodysplastic syndrome (MDS), increased TIM-3 expression on TH1 cells, regulatory T cells, CD8+ T cells, and hematopoietic stem cells
Mahnaz Rezaei, Jiaxiong Tan, Chengwu Zeng, Yangqiu Li, Mazdak Ganjalikhani-Hakemi, Mazdak Ganjalikhani-Hakemi   +5 more
doaj   +3 more sources

TIM-3 expression in breast cancer [PDF]

OncoImmunology, 2018
Tumor-infiltrating lymphocytes (TILs) are predominantly present in breast cancer patients with estrogen receptor negative tumors, among whom increasing levels correlate with favorable outcomes.
Samantha Burugu, Dongxia Gao, Samuel Leung, Stephen K. Chia, Torsten O. Nielsen   +4 more
doaj   +3 more sources

Immune checkpoint TIM-3 regulates microglia and Alzheimer's disease. [PDF]

Nature
Kimura K, Subramanian A, Yin Z, Khalilnezhad A, Wu Y, He D, Dixon KO, Chitta UK, Ding X, Adhikari N, Guzchenko I, Zhang X, Tang R, Pertel T, Myers SA, Aastha A, Nomura M, Eskandari-Sedighi G, Singh V, Liu L, Lambden C, Kleemann KL, Gupta N, Barry JL, Durao A, Cheng Y, Silveira S, Zhang H, Suhail A, Delorey T, Rozenblatt-Rosen O, Freeman GJ, Selkoe DJ, Weiner HL, Blurton-Jones M, Cruchaga C, Regev A, Suvà ML, Butovsky O, Kuchroo VK.   +39 more
europepmc   +2 more sources

Tim-3 [PDF]

médecine/sciences, 2018
Les lymphocytes T (LT) exprimant de multiples molécules de co-stimulation inhibitrices (PD-1, Tim-3, Lag-3, etc.) perdent leur activité anti-tumorale. PD-1 est une cible thérapeutique majeure dans le traitement du cancer, mais son expression isolée ne signe pas une dysfonction.
Clémence Granier, Alain Gey, Charles Dariane, Arnaud Mejean, Marc-Olivier Timsit, Charlotte Blanc, Virginie Verkarre, Camélia Radulescu, Elisabeth Fabre, Yann Vano, Stéphane Oudard, Cécile Badoual, Éric Tartour   +12 more
openaire   +2 more sources

Phosphatidylserine binding directly regulates TIM-3 function [PDF]

Biochemical Journal, 2021
Co-signaling receptors for the T cell receptor (TCR) are important therapeutic targets, with blockade of co-inhibitory receptors such as PD-1 now central in immuno-oncology. Advancing additional therapeutic immune modulation approaches requires understanding ligand regulation of other co-signaling receptors.
Courtney M. Smith, Alice Li, Nithya Krishnamurthy, Mark A. Lemmon   +3 more
openaire   +2 more sources

Power Imbalance in Collaboration Relationships [PDF]

International Journal of Supply and Operations Management, 2016
Power plays a significant role in many organizational theories such as resource dependency theory and transaction cost economics. It allows the strong companies to win more than others, or more broadly, to coerce others to do what they would not ...
Driss Essabbar, Maria Zrikem, Marc Zolgadri   +2 more
doaj   +3 more sources

Immune regulation by Tim-3 [PDF]

F1000Research, 2018
T-cell immunoglobulin and mucin domain 3 (Tim-3) is a transmembrane protein that in both mice and humans has been shown to possess various functions in a context-dependent manner. Thus, Tim-3 has been associated with both inhibitory and co-stimulatory function, depending in part on the specific cell type and immune response course.
Hridesh Banerjee, Lawrence P. Kane
openaire   +2 more sources

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Journal of Hematology & Oncology, 2023
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies.
Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yang Li   +4 more
semanticscholar   +1 more source

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

Nature Communications, 2021
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion and immunotherapy efficacy; however, the molecular mechanism is ...
Riyao Yang, Linlin Sun, Ching-Fei Li, Yu-Han Wang, Jun Yao, Hui Li, Meisi Yan, Wei-Chao Chang, Jung-Mao Hsu, Jong-Ho Cha, J. Hsu, Cheng-Wei Chou, Xian Sun, Yalan Deng, C. Chou, Dihua Yu, M. Hung   +16 more
semanticscholar   +1 more source